Medication Reconciliation in Hospitalized CKD Patients : A Quasi-Experimental Study

NCT06819527 | Completed

• 1 other identifier: Grant number: 20220257
• Study Type: interventional
• Target: 323
• Locations: 1 country
• Sites: 1

Brief Summary

This study aimed to evaluate the impact of combining medication reconciliation with medication review on reducing medication discrepancies at discharge and all-cause readmissions among CKD patients, in comparison to a retrospective control group that received usual care, which may or may not have included medication reconciliation.

Conditions

Chronic Kidney Disease(CKD)

Outcome Measures

Primary Outcomes (1)

• all-cause 90-day readmission

  The primary outcome in this study was the likelihood of all-cause 90-day readmission as extracted from medical records for both study groups

  90 days after discharge

Study Arms (2)

Intervention group

EXPERIMENTAL

interventional group, in which patients received a supplemented medication reconciliation service.

Other: Medication reconciliation service

Retrospective control group in which patients received the usual care

NO INTERVENTION

A retrospective control group in which patients received the usual care that may or may not include medication reconciliation

Interventions

Medication reconciliation service OTHER

Patients in the interventional group received medication reconciliation at admission and discharge in addition to continuous medication review during their admissions.

Intervention group

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult (18 years or older) admitted patients with CKD (stages 2-5 ), who were using at least three chronic medicines at home, and were hospitalized for at least 48 hours.

You may not qualify if:

• Patients with kidney transplantation .
• Patients who have difficulties in responding to interviews and did not have family member or caregiver on behave.
• Patients who refused to provide a written informed consent.

Sponsors & Collaborators

• Jordan University of Science and Technology: lead

Study Sites (1)

King Abdullah University Hospital and Princess Basma Hospital

Irbid, 22110, Jordan

Location

Related Publications (1)

• Abu Farha R, Yousef A, Gharaibeh L, Alkhalaileh W, Mukattash T, Alefishat E. Medication discrepancies among hospitalized patients with hypertension: assessment of prevalence and risk factors. BMC Health Serv Res. 2021 Dec 14;21(1):1338. doi: 10.1186/s12913-021-07349-5.

  PMID: 34903221 BACKGROUND

MeSH Terms

Conditions

Renal Insufficiency, Chronic

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: This was a quasi-experimental trial

Study Record Dates

• First Submitted: February 5, 2025
• First Posted: February 11, 2025
• Study Start: February 1, 2023
• Primary Completion: August 30, 2023
• Study Completion: August 30, 2023
• Last Updated: January 29, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

JO (1)